14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Pharmacological evaluation and docking studies ofa,ß-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and proinflammatory cytokines.

Universiti Kebangsaan Malaysia
Structural modifications of coumarin derivatives: Determination of antioxidant and lipoxygenase (LOX) inhibitory activity.

TBA
Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: synthesis, cytostatic and antioxidative activity.

University of Zagreb
Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.

University of Alberta
New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment.

Iqog, Csic
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.

China Pharmaceutical University
Dual antioxidant structures with potent anti-inflammatory, hypolipidemic and cytoprotective properties.

Aristotelian University of Thessaloniki
Azaphenothiazines - promising phenothiazine derivatives. An insight into nomenclature, synthesis, structure elucidation and biological properties.

The Medical University of Silesia
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.

Abbottabad University of Science and Technology
Substituted pyridines as sodium channel blockers

Purdue Pharma
Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists

Bristol-Myers Squibb
Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.

National Cancer Institute-Bethesda
Discovery of a novel class of selective human CB1 inverse agonists.

Vernalis (R&D)